Verrica Pharmaceuticals Inc.

VRCA

US92511W1080

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 01:30:00 18/05/2024 am IST			5-day change	1st Jan Change
8.67 ^USD	-5.04%		+8.38%	+18.44%

15/05	Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth	MT
15/05	Verrica Pharmaceuticals Inc. Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study Ycanth for the Treatment of Common Warts	CI

Verrica Pharmaceuticals Inc. Announces Passing of Board of Directors Member Glenn Oclassen

November 19, 2019 at 05:30 pm IST

Verrica Pharmaceuticals Inc. announced the passing of Glenn Oclassen, a valued member of the company’s Board of Directors. Mr. Oclassen passed away on November 13, 2019. Mr. Oclassen joined the company's Board of Directors in December, 2015. He was formerly the President and Chief Executive Officer, and a director, of Transcept Pharmaceuticals.

Latest news about Verrica Pharmaceuticals Inc.

Verrica Pharmaceuticals Amends Licensing Agreement With Torii Pharmaceutical for Phase 3 Trial of Ycanth	15/05	MT
Verrica Pharmaceuticals Inc. Announces Amendment to Collaboration and License Agreement with Torii Pharmaceutical Co. Ltd. to Fund Global Pivotal Phase 3 Clinical Trial to Study Ycanth for the Treatment of Common Warts	15/05	CI
HC Wainwright Adjusts Price Target on Verrica Pharmaceuticals to $14 From $13, Maintains Buy Rating	14/05	MT
Needham Adjusts Price Target on Verrica Pharmaceuticals to $16 From $8, Keeps Buy Rating	14/05	MT
Transcript : Verrica Pharmaceuticals Inc., Q1 2024 Earnings Call, May 13, 2024	13/05
Verrica Pharmaceuticals Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	13/05	CI
Earnings Flash (VRCA) VERRICA PHARMACEUTICALS Reports Q1 Revenue $3.8M, vs. Street Est of $2.7M	13/05	MT
Verrica Pharmaceuticals' Ycanth Gets New Chemical Entity Status, Orange Book Listing	27/03	MT
Verrica Pharmaceuticals Announces that YCANTH? Receives New Chemical Entity Status and Orange Book Listing from the FDA	26/03	CI
HC Wainwright Adjusts Verrica Pharmaceuticals Price Target to $13 From $12, Maintains Buy Rating	01/03	MT
Transcript : Verrica Pharmaceuticals Inc., Q4 2023 Earnings Call, Feb 29, 2024	29/02
Verrica Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	29/02	CI
Verrica Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	29/02	CI
Earnings Flash (VRCA) VERRICA PHARMACEUTICALS Reports Q4 Revenue $2M, vs. Street Est of $950,000	29/02	MT
Verrica Pharmaceuticals Sues Dormer Labs for Promoting Unapproved Cantharidin Drugs in US	05/02	MT
Verrica Pharmaceuticals Receives Permanent J-Code for YCANTH from Centers for Medicare and Medicaid Services	29/01	CI
Ligand Pharma's at-home skin treatment gets FDA approval	06/01	RE
Verrica Pharmaceuticals Inc. Announces Last Patient Dosed in Part 2 of Phase 2 Study of VP-315	06/01	CI
Lytix Biopharma’s License Partner Finalizes Patient Dosing in Phase 2 Trial of Skin Cancer Therapy	05/01	MT
Verrica Pharmaceuticals Doses Last Patient in Part 2 of Phase 2 Study of Potential Skin Cancer Treatment	05/01	MT
Verrica Pharmaceuticals Announces Receipt of Minutes from Type C Meeting with FDA Regarding Clinical Development of YCANTH?? for the Treatment of Common Warts	04/01	CI
Verrica Pharmaceuticals Partners With Walgreens to Distribute YCANTH Therapy	03/01	MT
Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH?	03/01	CI
Sector Update: Health Care Stocks Retreating Late Afternoon	16/12	MT
Sector Update: Health Care	16/12	MT

Chart Verrica Pharmaceuticals Inc.

Duration

Period

More charts

Company Profile

Verrica Pharmaceuticals Inc. is a dermatology therapeutics company. The Company is focused on developing and commercializing treatments for skin diseases. Its product pipeline consists of three product candidates: YCANTH, VP-315 and VP-103. YCANTH is a proprietary drug-device combination that contains a GMP-controlled formulation of cantharidin. We are also developing YCANTH for potential follow-on indications for the treatment of common warts and external genital warts. In addition, the Company is also developing YCANTH for the treatment of external genital warts, or external genital warts EGW. Its second candidate, VP-315, is an oncolytic peptide-based injectable therapy for the potential treatment of dermatology oncologic conditions, including basal cell carcinoma, non-metastatic melanoma, and non-metastatic Merkel cell carcinoma. VP-103, a second cantharidin based drug device combination for the potential treatment of plantar warts.

Sector

Pharmaceuticals

Calendar

06/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Verrica Pharmaceuticals Inc.

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

8.67 USD

Average target price

14.17 USD

Spread / Average Target

+63.40%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
VERRICA PHARMACEUTICALS INC.	+18.44%	37Cr
ELI LILLY AND COMPANY	+32.09%	69TCr
NOVO NORDISK A/S	+29.39%	58TCr
JOHNSON & JOHNSON	-1.34%	37TCr
MERCK & CO., INC.	+20.34%	33TCr
ABBVIE INC.	+7.39%	29TCr
ASTRAZENECA PLC	+13.85%	24TCr
ROCHE HOLDING AG	-3.03%	21TCr
NOVARTIS AG	+10.02%	21TCr
AMGEN INC.	+8.49%	17TCr

Other Pharmaceuticals